A recent study indicates that individuals who discontinue new GLP-1 drugs like Wegovy and Mounjaro tend to recover reduced body mass far faster than those who stop traditional diet and exercise plans.
Published data in a leading health publication points out that while overweight individuals can lose about a fifth of their body weight while on the medication, the weight is regained at an estimated rate of 0.8 kg per month after stopping.
"Individuals purchasing such treatments must be cognizant of the potential of rapid rebound weight gain when the treatment is stopped," warns researcher Dr. Susan Jebb.
This pace of regain means a return to pre-treatment weight within about a year and a half.
Analyzing Approaches
The study, which looked at dozens of studies involving thousands of patients, compared the results of these new drugs with older methods.
Researchers emphasize that individuals who shed pounds through lifestyle changes alone usually see a less rapid creep back—around 100 grams monthly—post-intervention.
Understanding the Rapid Rebound
Nutrition scientists propose the mechanism of the drugs accounts for the heightened regain.
The injections copy a body's own chemical called GLP-1, which moderates appetite.
"Artificially providing GLP-1 levels several times higher than normal might result in the body to generate a reduced amount of its endogenous GLP-1, and may also lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Stopping of this medication results in appetite is no longer kept in check, making overeating much more probable."
An Ongoing Issue?
Medical guidelines advise the injections for individuals with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
Many experts contend that, considering the significant potential of weight regain, the treatment should be considered long-term.
This opinion is supported by drug manufacturers, who note that the findings "underscore the persistent nature of excess weight," comparing it to managing conditions like high blood pressure.
User Accounts
People who have stopped the medication report a powerful return of cravings.
"I experienced something flipping and you're instantly starving," described one woman.
The struggle is compounded if users have not adopted permanent dietary or behavioural modifications during treatment.
Widespread Adoption
Figures show that millions of people in the UK have used these injections in the past year, with desire remaining high.
- Use is higher among females compared to men.
- The 40s and 50s demographic shows the greatest usage rates.
- Many obtain the drugs through private healthcare rather than public health services.
In conclusion, clinicians stress that while these medications are effective agents for weight loss, they are not a standalone solution and maintained weight loss likely depends on integrated behavioural support.
